LivaNova pairs a leadership-positioned Essenz upgrade cycle and recurring surgical consumables with double-digit neuromodulation growth, supporting a $155.88 probability-weighted five-year target despite execution and reimbursement risks.
Overview
LivaNova is a specialized medtech manufacturer formed in 2015, with Cardiopulmonary and Neuromodulation franchises serving hospitals and specialist clinicians. Cardiopulmonary pairs global leadership in heart-lung machines with recurring, high-margin oxygenators and tubing; Neuromodulation sells VNS systems for drug-resistant epilepsy and is expanding into OSA with FDA-approved aura6000. Q3 2026 revenue rose 9.9% reported to $393.15 million, beating consensus by $12.04 million, while adjusted EPS of $1.23 beat by $0.17. Adjusted operating margin expanded 100 basis points to 23.5%; legal costs of $39.8 million contributed to GAAP EPS of $0.11. Management raised 2026 constant-currency revenue growth guidance to 9.0%–10.0% and adjusted EPS guidance to $4.40–$4.50, while reaffirming $140–$160 million adjusted FCF. **The Essenz replacement cycle and recurring consumables support durable core growth**, complemented by double-digit VNS growth and new OSA/TRD opportunities. At roughly $90–$94, shares traded at 20.0x–20.6x 2026E adjusted EPS, below Boston Scientific’s approximately 28x P/E but above Medtronic’s approximately 18x. **The report’s probability-weighted five-year target is $155.88**, with near-term catalysts including raised guidance, ongoing Essenz placements, CMS reimbursement support, and aura6000 commercialization.